High-powered lasers and the need to rethink the wRVUs for stone procedures
Urologist Henry Rosevear, MD, turns his focus to the topic of evolving approaches to treating stones—and how urologists are compensated for these procedures.
Related Articles
Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec
Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.
Ernest Morton, MD, shares initial findings on the use of an AI scribe
“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA,…
Juan Andino, MD, highlights SUO session on telehealth in urology
“Without Congressional action, all the progress that has been made—the new normal, so to speak—that patients, physicians, and providers alike have become used to, is…
Expert on Aquablation’s comparable long-term outcomes in prostates of different sizes
“I think [for] the consistency, we can give [a lot of] credit to the fact that Aquablation gives a lot of precision in terms of…
Sandip Prasad, MD, on UGN-102’s potential as a non-surgical option in NMIBC
“The durability response for these patients was impressive given the fact that these patients were those who, by definition and by inclusion criteria, were recurrent…
Evolving Role of Biomarkers in Prostate Cancer
Dr Lowentritt introduces an upcoming series revolving around biomarker utilization in prostate cancer treatment.
Quiz: CUA guidelines on germline genetic testing in prostate cancer
Test your knowledge of his quiz the Canadian Urological Association’s recommendations for germline genetic testing in prostate cancer management.
The potential of HER2 targeting in prostate cancer: A case study with trastuzumab deruxtecan
“That pan-tumor approval and this patient case really highlight that in prostate cancer, we should be checking HER2 by immunohistochemistry,” says Maneesh R. Jain, MD.
Eric Jonasch, MD, shares pooled safety data on belzutifan in advanced RCC
“We did see that there was a certain percentage of individuals who had to have dose holding, and a smaller percentage of people had to…
What drives malpractice lawsuits involving testicular cancer?
“We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to…